James Hamilton - 04 Jan 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role: Senior Vice President
Signature: /s/ James Hamilton
Issuer symbol: ARWR
Transactions as of: 04 Jan 2022
Transactions value $: -$1,654,591
Form type: 4
Filing time: 06 Jan 2022, 19:56:31 UTC
Previous filing: 04 Jan 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARWR	Common Stock	Sale	-$646K	-9.96K	-5.49%	$64.89	171K	04 Jan 2022	Direct	F1, F2
transaction	ARWR	Common Stock	Sale	-$490K	-7.47K	-4.36%	$65.59	164K	04 Jan 2022	Direct	F1, F3
transaction	ARWR	Common Stock	Sale	-$54K	-802	-0.49%	$67.39	163K	04 Jan 2022	Direct	F1, F4
transaction	ARWR	Common Stock	Sale	-$44.2K	-649	-0.4%	$68.12	162K	04 Jan 2022	Direct	F1, F5
transaction	ARWR	Common Stock	Sale	-$34.7K	-500	-0.31%	$69.38	162K	04 Jan 2022	Direct	F1, F6
transaction	ARWR	Common Stock	Sale	-$139K	-2.29K	-1.41%	$60.51	160K	05 Jan 2022	Direct	F1, F7
transaction	ARWR	Common Stock	Sale	-$130K	-2.1K	-1.32%	$61.84	157K	05 Jan 2022	Direct	F1, F8
transaction	ARWR	Common Stock	Sale	-$68.9K	-1.1K	-0.7%	$62.64	156K	05 Jan 2022	Direct	F1, F9
transaction	ARWR	Common Stock	Sale	-$44.6K	-700	-0.45%	$63.68	156K	05 Jan 2022	Direct	F1, F10
transaction	ARWR	Common Stock	Sale	-$3.86K	-60	-0.04%	$64.35	156K	05 Jan 2022	Direct	F1, F11

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 to $65.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 to $66.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.62 to $67.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.67 to $68.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.00 to $69.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F7	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $60.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F8	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.09 to $62.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F9	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.15 to $63.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F10	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.16 to $63.95, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F11	Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.